NEW YORK (GenomeWeb News) – Rosetta Genomics said today that it will collaborate with researchers at the MD Anderson Cancer Center and the Kleberg Center for Molecular Markers to develop a microRNA-based test to predict risk of disease recurrence in lung cancer patients who have undergone curative resection.
The partners said patients with high risk of recurrence may benefit from adjuvant therapy after surgical resection, but low-risk patients may be exposed to unnecessary toxicities.
They hope to develop a test that will enable physicians to distinguish between patients with high risk and low risk of recurrence, which would help them optimize treatment regimens.
“By leveraging microRNAs’ unique sensitivity as biomarkers, we have an opportunity to develop a novel test that will assist clinicians and patients to better manage this type of cancer,” Ignacio Wistuba, associate professor in the department of pathology at MD Anderson Cancer, said in a statement.
The Kleberg Center for Molecular Markers is part of MD Anderson.